Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer (ISCAN)
Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study
Sponsor: Changhai Hospital
Listed as NCT01404260, this PHASE3 trial focuses on Non-small Cell Lung Cancer and remains completed. Sponsored by Changhai Hospital, it has been updated 9 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
-
Oct 2021 — Dec 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
- First People's Hospital of Hangzhou
- Fudan University
- Guangdong Association of Clinical Trials
- Henan Cancer Hospital
- Jiangsu Cancer Institute & Hospital
- NanJing PLA 81 Hospital
- Nanjing PLA General Hospital
- Ruijin Hospital
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Sir Run Run Shaw Hospital
- The First Affiliated Hospital of Soochow University
- The First Hospital of Jilin University
- Wuxi No. 4 People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .